Intensity Therapeutics, Inc. collaborated with Merck to evaluate INT230-6 in combination with KEYTRUDA in advanced solid malignancies.

Intensity Therapeutics is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. We leverage our DfuseRxSM technology platform to create new drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Our lead product candidate, INT230-6, is currently being evaluated in a Phase 1/2 clinical study in patients with various types of advanced solid tumors. INT230-6 has the potential to induce an adaptive immune response that not only attacks the injected tumor, but also non-injected tumors and unseen micro-metastases. Intensity is based in Westport, Connecticut. For more information, please visit www.intensitytherapeutics.com and follow us on Twitter @IntensityInc.

Founded 2012